Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy S Bailey

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Journal of Diabetes Science and Technology|October 16, 2014
Usability and training differences between two personal insulin pumpsNoel E Schaeffer, Linda J Parks, Erik T Verhoef, et al.
Diabetes Technology & Therapeutics|July 4, 2012
Performance of a new blood glucose monitoring system in the hands of intended usersTimothy S Bailey, Jane F Wallace, Joan Lee Parkes, et al.
JAMA|July 4, 2017
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical TrialWendy Lane, Timothy S Bailey, Gregg Gerety, et al.
Advances in Therapy|July 31, 2019
Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L TrialLawrence Blonde, Timothy S Bailey, Jason Chao, et al.
Diabetes, Obesity & Metabolism|July 31, 2020
A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control studyLuigi F Meneghini, Sean D Sullivan, Gerry Oster, et al.
Journal of Diabetes Science and Technology|December 10, 2021
Needle Technology for Insulin Administration: A Century of InnovationLutz Heinemann, Trung Nguyen, Timothy S Bailey, et al.
Diabetes, Obesity & Metabolism|December 23, 2017
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulinFang Liz Zhou, Fen Ye, Paulos Berhanu, et al.
Diabetes Technology & Therapeutics|November 7, 2022
Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set WearJasmin R Kastner, Timothy S Bailey, Poul Strange, et al.
Diabetes, Obesity & Metabolism|June 26, 2018
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort studySean D Sullivan, Timothy S Bailey, Ronan Roussel, et al.
Lancet (London, England)|June 25, 2025
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trialAthena Philis-Tsimikas, Richard M Bergenstal, Timothy S Bailey, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Journal of Diabetes Science and Technology|October 16, 2014
Usability and training differences between two personal insulin pumpsNoel E Schaeffer, Linda J Parks, Erik T Verhoef, et al.
Diabetes Technology & Therapeutics|July 4, 2012
Performance of a new blood glucose monitoring system in the hands of intended usersTimothy S Bailey, Jane F Wallace, Joan Lee Parkes, et al.
JAMA|July 4, 2017
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical TrialWendy Lane, Timothy S Bailey, Gregg Gerety, et al.
Advances in Therapy|July 31, 2019
Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L TrialLawrence Blonde, Timothy S Bailey, Jason Chao, et al.
Diabetes, Obesity & Metabolism|July 31, 2020
A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control studyLuigi F Meneghini, Sean D Sullivan, Gerry Oster, et al.
Journal of Diabetes Science and Technology|December 10, 2021
Needle Technology for Insulin Administration: A Century of InnovationLutz Heinemann, Trung Nguyen, Timothy S Bailey, et al.
Diabetes, Obesity & Metabolism|December 23, 2017
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulinFang Liz Zhou, Fen Ye, Paulos Berhanu, et al.
Diabetes Technology & Therapeutics|November 7, 2022
Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set WearJasmin R Kastner, Timothy S Bailey, Poul Strange, et al.
Diabetes, Obesity & Metabolism|June 26, 2018
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort studySean D Sullivan, Timothy S Bailey, Ronan Roussel, et al.
Lancet (London, England)|June 25, 2025
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trialAthena Philis-Tsimikas, Richard M Bergenstal, Timothy S Bailey, et al.
Pageof 11